Background Steroid‐sparing strategies have been attempted in recent decades to avoid
morbidity from long‐term steroid intake among kidney transplant recipients. Previous …

Since the introduction of pancreas transplantation more than 40 years ago, efforts to develop
more minimally invasive techniques for endocrine replacement therapy have been in …

Background There are few comparisons of antibody induction therapy allowing early
glucocorticoid withdrawal in renal-transplant recipients. The purpose of the present study …

In a randomized, open-label, multicenter study, de novo renal transplant patients received
no steroids (n= 112), steroids to day 7 (n= 115), or standard steroids (n= 109) with …

Allogeneic immune responses are modulated by a subset of host T cells with regulatory
function (Treg) contained within the CD4+ CD25 high subset. Evidence exists that Treg …

Transplant patients are at the risk for posttransplant lymphoproliferative disease (PTLD), a
virally‐driven malignancy. Induction with the depleting antibody preparations Thymoglobulin …

Significant advancements in solid organ transplantation immunosuppressive medications
and regimens have resulted in improved outcomes over the years. A multidrug approach …

Abstract Alemtuzumab (Campath-1H) is a powerful antilymphocyte antibody that produces
profound and long-lasting lymphopenia. It is being used with increasing frequency for …

Exceptionally low acute rejection rates and excellent graft survival can be achieved with
cyclosporine and tacrolimus (CNI)-based immunosuppressive protocols that incorporate …

As the most prevalent pathogen among transplant patients, cytomegalovirus (CMV) affects
up to three‐quarters of all solid organ transplant recipients. While we have made great …